{"entity":{"id":"nct06235229","kind":"trial","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of GC012F in multiple myeloma, run by Gracell Biotechnologies (Shanghai) Co., Ltd., now recruiting.","summary":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06235229 by Gracell Biotechnologies (Shanghai) Co., Ltd., with 110 participants planned, started 2023-12-26 and due to reach its primary completion in 2026-03-02. Interventions recorded: GC012F. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06235229","url":"https://clinicaltrials.gov/study/NCT06235229"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["gc012f"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06235229","phase":"1/2","setting":"A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","enrolled":110,"outcomes":[]},"route":"/trials/nct06235229/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"gc012f","kind":"drug","name":"GC012F","route":"/drugs/gc012f/"}]}}